Literature DB >> 9721781

Intravenous nitroglycerin for internal podalic version of the second twin in transverse lie.

P Dufour1, D Vinatier, S Vanderstichele, A S Ducloy, S Depret, J C Monnier.   

Abstract

OBJECTIVE: To report our experience with high doses (0.1-0.2 mg per 10 kg pregnant weight) of intravenous (IV) nitroglycerin as a uterine relaxing agent for managing internal podalic version of the second twin in transverse lie with unruptured membranes.
METHODS: Between August 1994 and December 1997, we managed 22 cases of internal podalic version of the second twin with the administration of high doses of IV nitroglycerin.
RESULTS: Twenty internal podalic versions were completed successfully, and two cases failed. One failure was considered not related to IV nitroglycerin because the patient had a panic attack, requiring general anesthesia for sedation. The internal podalic version then succeeded. The patient with true failure of IV nitroglycerin required emergency cesarean because of acute fetal bradycardia and a nonrelaxed uterus. This was the only nontransverse lie, but with a very high face presentation. One internal podalic version was complicated by hemorrhage (2000 mL).
CONCLUSION: Intravenous nitroglycerin to induce uterine atonia, with epidural analgesia, avoids general anesthesia and makes internal podalic version easier. In 22 cases (with success in 20) of internal podalic version of the second twin in transverse lie with unruptured membranes, IV nitroglycerin induced transient and prompt uterine relaxation without affecting maternal and fetal outcomes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9721781     DOI: 10.1016/s0029-7844(98)00231-2

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  1 in total

1.  Manipulative Reduction for Abnormal Uterine Inclination in Vaginal Delivery.

Authors:  Jia Chen; Yujuan Yuan; Yadong Wang
Journal:  Comput Math Methods Med       Date:  2022-01-30       Impact factor: 2.238

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.